Financials

Revenue Bifurcation

Due to a sustainable growth strategy and robust business model, Intas has achieved a healthy top and bottom line, year on year. The company’s successful track record of landmark acquisitions is built entirely on the foundation of robust financial strength.

financial-image
2019(March) 2018(March) 2017(March) 2016(March) 2015(March)

Financial Summary


(US$ Mn)

Revenue from Operations

1884

Profit after Tax

204

Net Block including CWIP

1281

Profit before Interest, Depreciation & Tax

359

Financial Summary


(US$ Mn)

Revenue from Operations

1576

Profit after Tax

198

Net Block including CWIP

1224

Profit before Interest, Depreciation & Tax

356

Financial Summary


(US$ Mn)

Revenue from Operations

1213

Profit after Tax

149

Net Block including CWIP

1058

Profit before Interest, Depreciation & Tax

256

Financial Summary


(US$ Mn)

Revenue from Operations

946

Profit after Tax

128

Net Block including CWIP

373

Profit before Interest, Depreciation & Tax

206

Financial Summary


(US$ Mn)

Revenue from Operations

745

Profit after Tax

81

Net Block including CWIP

370

Profit before Interest, Depreciation & Tax

144

 

company-logo

Corporate Office

Intas Pharmaceuticals Ltd.

Corporate House, Near Sola Bridge, S. G.

Highway, Thaltej, Ahmedabad – 380054.

Gujarat. India.

call-icon+91 79 6157 7000

email-icongeneralqueries@intaspharma.com

Follow us on linkedin

© 2019 Intas Pharmaceuticals Ltd.

All rights reserved.